The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase I dose-escalation, open-label study of HSP990 administered orally in adult patients with advanced solid malignancies.
Leticia De Mattos-Arruda
No relevant relationships to disclose
Lillian L. Siu
Employment or Leadership Position - Agios (I); Bayer (Other); Boehringer Ingelheim; Bristol-Myers Squibb; Celgene (Other); EntreMed (I); GlaxoSmithKline (Other); Merck (Other); Novartis (Other); Pfizer Inc. (Other); Regeneron (Other)
Consultant or Advisory Role - Boehringer Ingelheim; Oncoethix
Stock Ownership - Agios (I); EntreMed (I); Rigel Pharmaceuticals Inc. (I)
Javier Cortes
Consultant or Advisory Role - Celgene; Novartis; Roche
Honoraria - Celgene; Eisai; Novartis; Roche
Yann Berge
No relevant relationships to disclose
Albiruni R A Razak
No relevant relationships to disclose
Jordi Rodon Ahnert
Consultant or Advisory Role - Lilly; Lipopharma; Novartis; SERVIER
Ewa Cottura
No relevant relationships to disclose
Philippe Bedard
Consultant or Advisory Role - Novartis
Research Funding - Novartis
Mikhail Akimov
Employment or Leadership Position - Novartis
Stock Ownership - Novartis
Hong Lu
Employment or Leadership Position - Novartis
Stock Ownership - Novartis
Scott Pain
Employment or Leadership Position - Novartis
Audrey Kaag
Employment or Leadership Position - Novartis
Jean-Pierre Delord
No relevant relationships to disclose